Effect of resveratrol on lipid profile: An updated systematic review and meta-analysis on randomized clinical trials

Abstract

Despite the notion that resveratrol can significantly reduce plasma lipids, the result of randomized clinical trials (RCTs) on resveratrol effect and the serum lipid profile are contradictory. Our objective was to conduct a systematic review and meta-analysis on randomized clinical trials (RCTs) and assess the effect of resveratrol on lipids. ISI web of science, Ovid, PubMed/Medline, SCOPUS, and Google Scholar data bases were searched up to Jun 2017. RCTs that assessed resveratrol effects on lipid profile among adult participants were chosen. Treatment effects were considered as weighted mean difference (WMD) and the corresponding standard error (SE) in concentrations of serum lipids. To estimate the overall summary effect, we used random-effects model. The protocol was registered with PROSPERO (No. CRD42017072365). This meta-analysis was performed on twenty-one trials. Our results indicated that resveratrol can't significantly change total cholesterol (TC) (WMD = -0.08 mmolil, 95 CI: -0.23, 0.08; P =.349, I-2 = 87.8), low-density lipoprotein (LDL-C) (WMD: -0.04 mmolil, 95 CI: -0.21, 0.12; P = .620, I-2 = 93.4), and high density lipoprotein (HDL-C) (WMD: -0.01 mmol/l, 95 CI: -0.04, -0.02; P = .269, I-2 = 88.6). Its effect on triacylglycerol (TG) (WMD: 0.58 mmol/l, 95 CI: 0.34, 0.82; P <.0001, I-2 = 99.8), was significant, but after removing one study the significance was eliminated. We also found that sex, age, BMI, resveratrol dosage, and intervention duration could not change the results. We conclude that resveratrol does not change lipid profile concentration. Confirmation of this conclusion will require more studies exclusively on dyslipidemic patients in which the intake of lipid lowering agents is among the exclusion criteria. (C) 2018 Elsevier Ltd. All rights reserved.